Immunopharmacology of CpG oligodeoxynucleotides and ribavirin.
To investigate their potential mechanisms of action, the nucleoside analogue ribavirin and a TLR9 agonist were compared. The CpG oligodeoxynucleotides (ODN) demonstrated strong TLR9-related Th1-type effects, and ribavirin appeared only to mediate signaling in TLR-transfected cells. CpG ODN represent a promising new type of therapeutic drug for hepatitis C or other infectious diseases.
Vollmer
Jörg
J
Coley Pharmaceutical GmbH, Elisabeth-Selbert-Strasse 9, D-40764 Langenfeld, Germany. jvollmer@coleypharma.com
Rankin
Robert
R
Hartmann
Hanna
H
Jurk
Marion
M
Samulowitz
Ulrike
U
Wader
Tanja
T
Janosch
Andrea
A
Schetter
Christian
C
Krieg
Arthur M
AM
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D018925:Chemokines / Q000096:biosynthesis; D016207:Cytokines / Q000096:biosynthesis; D004268:DNA-Binding Proteins / Q000819:agonists*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D016328:NF-kappa B / Q000187:drug effects; D009841:Oligonucleotides / Q000494:pharmacology*; D011956:Receptors, Cell Surface / Q000819:agonists*; D012254:Ribavirin / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D018417:Th1 Cells / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D018418:Th2 Cells / Q000187:drug effects / Q000378:metabolism; D051217:Toll-Like Receptor 9; D014162:Transfection
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D018925:Chemokines; D016207:Cytokines; D004268:DNA-Binding Proteins; D016328:NF-kappa B; D009841:Oligonucleotides; D011956:Receptors, Cell Surface; C495371:TLR9 protein, human; D051217:Toll-Like Receptor 9; D012254:Ribavirin